SCHEMBL1839368

SCHEMBL1839368

C[C@@H]1C[C@H]1C(=O)Nc1snc(-c2ccc(Cl)c(Cl)c2)c1Br

nearest known ligand 0.78

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 20/20 0.78
GRM5 P41594 15/20 0.78
HTR2B P41595 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1839372 1.00 GRM1 (0.78) GRM1GRM5HTR2B
SCHEMBL1839370 1.00 GRM1 (0.78) GRM1GRM5HTR2B
SCHEMBL1839361 0.88 GRM1 (1.00) GRM1GRM5
SCHEMBL1839364 0.88 GRM1 (1.00) GRM1GRM5
SCHEMBL1839366 0.88 GRM1 (1.00) GRM1GRM5
SCHEMBL1838038 0.83 GRM1 (0.77) GRM1GRM5
SCHEMBL1838041 0.83 GRM1 (0.77) GRM1GRM5
SCHEMBL1838034 0.83 GRM1 (0.77) GRM1GRM5
SCHEMBL1839286 0.82 GRM1 (0.76) GRM1GRM5
SCHEMBL1839283 0.82 GRM1 (0.76) GRM1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960419-B2 Substituted carboxamides ELI LILLY AND COMPANY (US) 2011-06-14 US disclosed
EP-2076502-B1 SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2011-05-18 EP disclosed
US-20090182025-A1 SUBSTITUTED CARBOXAMIDES ELI LILLY AND COMPANY 2009-07-16 US disclosed
EP-2076502-A2 SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2009-07-08 EP disclosed
WO-2008103185-A2 SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182025-A1 SUBSTITUTED CARBOXAMIDES CNR2, TRPV1, CNR1 GRM1 675/4885GRM5 507/4885HTR2B 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.